10月9日，CRISPR Therapeutics盘中上涨5.31%，报53.05美元/股，成交额2887.24万美元。
消息面上，美国银行将CRISPR Therapeutics目标价从82美元小幅下调至81美元，同时维持买入评级。FactSet调查显示，该股分析师平均评级为增持，平均目标价为84.67美元，仍显著高于当前股价水平。
从基本面看，公司近期密集发布多项临床进展，包括CTX310在AHA科学会议及ESC大会上的积极数据，以及Zugo-cel在自身免疫疾病领域的Phase 1临床数据，多个后期催化剂有望逐步兑现。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.